Pharsight

1. Bonjesta patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7560122	DUCHESNAY	Pharmaceutical dosage form bearing pregnancy-friendly indicia	Jan, 2019 (5 years ago)
US9375404	DUCHESNAY	Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof	Feb, 2033 (8 years from now)
US9089489	DUCHESNAY	Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof	Feb, 2033 (8 years from now)
US9526703	DUCHESNAY	Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof	Feb, 2033 (8 years from now)
US9937132	DUCHESNAY	Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof	Feb, 2033 (8 years from now)

Market Authorisation Date: 07 November, 2016

Treatment: Treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
20 mg/20 mg	28 Aug, 2018	1	01 Mar, 2022	18 Feb, 2033	Deferred

Strength	Dosage	Availability
20MG;20MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7560122	DUCHESNAY	Pharmaceutical dosage form bearing pregnancy-friendly indicia	Jan, 2019 (5 years ago)
US6340695	DUCHESNAY	Rapid onset formulation	Jun, 2021 (2 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Apr 08, 2016

Market Authorisation Date: 08 April, 2013

Treatment: Treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management

Dosage: TABLET, DELAYED RELEASE;ORAL